BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17373717)

  • 1. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
    Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
    Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
    Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
    Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
    Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
    Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13.
    Nurmenniemi S; Kuvaja P; Lehtonen S; Tiuraniemi S; Alahuhta I; Mattila RK; Risteli J; Salo T; Selander KS; Nyberg P; Lehenkari P
    Exp Cell Res; 2010 Oct; 316(16):2676-82. PubMed ID: 20553713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
    Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lung cancer cells express functionally active Toll-like receptor 9.
    Droemann D; Albrecht D; Gerdes J; Ulmer AJ; Branscheid D; Vollmer E; Dalhoff K; Zabel P; Goldmann T
    Respir Res; 2005 Jan; 6(1):1. PubMed ID: 15631627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells.
    Di JM; Pang J; Pu XY; Zhang Y; Liu XP; Fang YQ; Ruan XX; Gao X
    Cancer Genet Cytogenet; 2009 Jul; 192(2):60-7. PubMed ID: 19596255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
    Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
    Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell.
    Xu L; Wang C; Wen Z; Yao X; Liu Z; Li Q; Wu Z; Xu Z; Liang Y; Ren T
    Immunol Lett; 2010 Jan; 127(2):93-9. PubMed ID: 19854217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion.
    Kauppila JH; Karttunen TJ; Saarnio J; Nyberg P; Salo T; Graves DE; Lehenkari PP; Selander KS
    APMIS; 2013 Jun; 121(6):511-22. PubMed ID: 23082743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas.
    Tanaka J; Sugimoto K; Shiraki K; Tameda M; Kusagawa S; Nojiri K; Beppu T; Yoneda K; Yamamoto N; Uchida K; Kojima T; Takei Y
    Int J Oncol; 2010 Oct; 37(4):805-14. PubMed ID: 20811701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
    Li N; Fan XG; Tang SE; Zhu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.
    Lim EJ; Lee SH; Lee JG; Chin BR; Bae YS; Kim JR; Lee CH; Baek SH
    FEBS Lett; 2006 Aug; 580(18):4533-8. PubMed ID: 16870179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides.
    Brownlie R; Zhu J; Allan B; Mutwiri GK; Babiuk LA; Potter A; Griebel P
    Mol Immunol; 2009 Sep; 46(15):3163-70. PubMed ID: 19573927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
    Li B; Zhang R; Li J; Zhang L; Ding G; Luo P; He S; Dong Y; Jiang W; Lu Y; Cao H; Zheng J; Zhou H
    Int Immunopharmacol; 2008 Mar; 8(3):379-89. PubMed ID: 18279792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
    Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
    Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.